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Abstract
Background: Evidences have shown that β1 and β2
adrenoceptors co-exist in human fibroblasts, but it is
not yet clear the functional expression of β3
adrenoceptor in these cells. The aim of this study
was to investigate the expression and biological effect
of β3 adrenoceptor activation in human skin fibroblast
and the different signaling pathways involved in its
effect. Methods: For this purpose in vitro cultures of
human skin fibroblast were established from human
foreskin and grown in Dulbecco’s modified Eagle’s
medium. The effect of ZD 7114 (β3 agonist) on cell
DNA synthesis, radioligand binding assay, cyclic GMP
and cyclic AMP accumulation and nitric oxide synthase
(NOS) activity were evaluated. Results: 3H-CGP
binding to human fibroblast membranes was a
saturable process to a single class of binding site.
The equilibrium parameters were: Kd 20±3 pM and
Bmax 222±19 fmol/mg protein. Ki values showed that
these cells express a high number of β3 adrenoceptor
subtypes. ZD 7114 stimulation of β3 adrenoceptor
exerts a concentration-dependent inhibition of DNA
synthesis and cAMP accumulation with parallel
increase in NOS activity that led to cGMP
accumulation. All these effects were blocked by the
β3 adrenoceptor antagonist (SR 59230A). The effect
of ZD 7114 on DNA synthesis significantly correlated
with its action either on cAMP or NOS-cGMP signaling
system. Inhibitors of NOS activity and NO-sensitive
guanylate cyclase prevented the inhibitory effect of
ZD 7114 on DNA synthesis. In addition, the β3
adrenoceptor-dependent increase in cGMP and
activation of NOS were blocked by the inhibition of
phospholipase C (PLC), calcium/calmodulin (CaM),
endothelial NOS activity and cGMP accumulation.
Conclusions: β3 adrenoceptor activation exerts
inhibitory effect on human fibroblast DNA synthesis
as a result of the activation of NO-cGMP pathway and
the inhibition of adenylate cyclase activity. The
mechanism appears to occurs secondarily to
stimulation of PLC and CaM. This in turn triggers
cascade reaction leading to increase production of
NO-cGMP with decrease in cAMP accumulation.
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Introduction
The human fibroblasts have been useful in the clinical
investigation of a variety of conditions due to its ease of
access and its potential for reflecting alterations in central
and systemic diseases. The fibroblast is the cell central
effective to wound healing and tissue remodeling and is
tightly regulated by many hormones and neurotransmitters
that govern its migration, extracellular matrix remodeling
and proliferation [1, 2].
As well as adrenergic receptors are implicated in
the modulation of normal cell proliferation, exerting a
negative or a positive control of cell proliferation depending
on the different cell types and the β adrenoceptor subtypes
expressed in the cells. It is also well known, that stimulation
of β1 or β2 adrenoceptors releases of Gs alpha which then
activates adenylate cyclase to produce cAMP
accumulation [3, 4], that in turn is able to modulate cell
proliferation [5]. Elevated levels of cAMP increases cell
proliferation via activation of cAMP-dependent protein
kinase A (PKA) and this PKA are responsible to cause
phosphorylation of β1 or β2 adrenoceptors leading to their
inactivation [6].
Substantial evidence exists that increase in cyclic
AMP modulates fibroblasts proliferation mediated by β
adrenergic receptors [7]. The positive action has been
observed on human cardiac fibroblasts [7-9] and the
negative action was previously reported on human
lymphocytes [10]. The human β2 adrenoceptor stimulation
has been the prototype for elucidating mechanisms of
human fibroblast proliferation [11]. But, even less is known
about β1 adrenoceptor stimulation that is also expressed
in active state on fibroblasts stimulating DNA synthesis
[12]. Atypical β adrenergic responses has been identified
with a novel receptor subtype, β3 adrenoceptor; first found
in brown fat cells [13], colon and gall bladder [14] and in
human ventricle [15]. Recently, a promiscuous coupling
between β3 adrenoceptor and Gs/Gi protein was
demonstrated [16]. There is an unusual biphasic effect
on cAMP production in response to β adrenoceptor
agonist; in which the agonist could either stimulate or
inhibit adenylate cyclase activity in adipocyte [16].
Furthermore, in some cell types, although β3
adrenoceptors are prominent, increases in cAMP occur
primarily through β1 or β2 adrenoceptors. The β3
adrenoceptor coupling to Gi could serve to restrain Gs
mediated activation of adenylate cyclase and to initiate
additional signal transduction pathways [16]. However,
there is little information on the additional signal
transduction pathway involved β3 in adrenoceptor-
mediated modulation of fibroblasts proliferation.
Cyclic GMP (cGMP) and substances that increase
cellular cGMP and nitric oxide (NO) – generating
molecules, inhibit the stimulation of DNA synthesis in
vascular smooth muscle cells, endothelial cells, mesangial
cells and cardiac fibroblasts [17-19]. Also, evidence exits
that cGMP is an antagonist of mitogen action in murine
fibroblasts decreasing cell proliferation [1]. A number of
years ago were demonstrated that fibroblast cell lines
contain particularly high activity of a guanylate cyclase
receptor and some fibroblast cell lines, also, appear to
contain a soluble guanylate cyclase responsive to NO
[20].
The purpose of the present study was to investigate
the effect of β3 adrenoceptor agonist on the human skin
fibroblast DNA synthesis. An additional purpose of this
study, was to examine the possibility that growth-inhibiting
β3 adrenoceptor activation is mediated by a cross talk




Pure cell cultures of neonatal human skin fibroblast were
established from the foreskin obtained after circumcision and
grown in Dulbecco’s modified Eagle’s medium (GIBCO)
supplemented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine and penicillin (100 U/ml) and streptomycin (100 µg/
ml) in a 5% CO2 environment at 37ºC described by Varani et al
[21]. The medium was replenished every 3-4 days. Confluent
cells were sub cultured by detaching the monolayer with 0.25%
trypsin in phosphate buffered saline solution (PBS). Cells of
passages 12-14 were used throughout. To identify the fibroblast
cultures and assay conditions, a series of experiments was
carried out to established incubation time and cell numbers.
The optimal conditions (sharp peak) for [3H] thymidine
incorporation were at 3-6 hours and was 2x104 the number of
cell growth. All the studies involving human subjects were
conducted according to the tenets of the Declaration of
Helsinki.
Measurement of DNA Synthesis
DNA synthesis was estimated by measurement of [3H]
thymidine (Dupont/New England Nuclear) incorporation into
trichloroacetic acid (TCA) – precipitable material. Cells growing
in the absence of 10% FBS were treated with different ZD 7114
concentrations for 3 hours and [3H]-thymidine (0.1 µCi/ml) was
added during the last hour. Cells were precipitated twice with
ice-cold 10% TCA. When antagonistic drugs and enzymatic
inhibitors were used, they were added 15 min before ZD 7114.
Cells were then removed with trypsin/PBS and radioactivity
was determined by liquid scintillation counting.
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Binding Assay
For the radioligand binding assays, cells were grown to
confluency in tissue culture dishes, quantitatively harvested
and collected by means of low-speed centrifugation (250 g).
The cells were resuspended in 5 volumes of 10 mM potassium
phosphate, 1 mM MgCl2, 0.25 M sucrose pH 7.5 (buffer A),
supplemented with 0.1 mM phenylmethylsulphonylfluoride
(PMSF), 2 µg/ml leupeptin and 1 µM pepstatin A and
homogenized in an Ultraturrax at 4ºC. Then, the homogenate
was centrifuged twice for 10 min a 3000 g, then at 10000 g and
40000 g at 4ºC for 15 and 90 min respectivelly. The resulting
pellets were resuspended in 50 mM phosphate buffer with the
same protease inhibitors pH 7.5 (buffer B). Receptor ligand
binding was performed as described previously [22]. Aliquot
of the membrane suspension (50 µg protein) were incubated
with increasing concentrations of [3H]-CGP (Dupont New
England Nuclear, Boston, MA, USA; Sp.Ac. 48.6 Ci/mmol) for
60 min at 25ºC in a total volume of 150 µl of buffer B. Binding
was stopped by adding 2 ml ice cold buffer followed by rapid
filtration (Whatman GF/c). Filters were rinsed with 12 ml of ice
cold buffer, transferred into vials containing 10 ml of scintillation
cocktail and counted in a liquid scintillation spectometer.
Nonspecific binding was determined in the presence of 1 µM
propranolol and never exceeded 10% of total binding.
Radioactivity bound was lower than 10% of total counts. For
competition binding assays, membranes were incubated with
about 0.51 nM [3H]-CGP alone and in the presence of increasing
concentration of adrenoceptor antagonists (nonspecific and
specific).
Determination of nitric oxide synthase activity (NOS)
Nitric oxide synthase (NOS) activity was measured in cells
by production of [U-14C]-citrulline from [U-14C]-arginine
according to the procedure described by Bredt, Ferris & Snyder
[23] and by Sterin-Borda et al. [24]. Briefly, after 20 min
preincubation in KRB solution, cells were transferred to 500 µl
of prewarmed KRB equilibrated with 5% CO2 in O2 in the
presence of [U-14C]-arginine (0.5 µCi). Appropriate
concentrations of drugs were added and the cells were incubated
for 20 min under 5% CO2 in O2 at 37°C. Measurement of basal
NOS activity in cells by the above mentioned procedure was
inhibited 95% in the presence of 0.5 mM NG-monomethyl-L-
arginine (L-NMMA). The results (pmol/g/tissue wet wt)
obtained for cells were expressed as the difference between
values in the absence (218 ± 18; n = 9) and in the presence (48
± 5, n = 9) of L-NMMA.
Cyclic GMP (cGMP) and Cyclic AMP (cAMP) assay
Cells were incubated in 1 ml KRB for 30 min and the β
agonist (ZD 7114) was added in the last 5 min. When blockers
were used, they were added 25 min before the addition of ZD
7114. After incubation, cells were homogenized in 2 ml of
absolute ethanol and centrifuged at 6.000 g for 15 min at 4°C.
Pellets were then rehomogenized in ethanol-water (2:1) and
supernatants collected and evaporated to dryness as indicated
above. Cyclic AMP or cyclic GMP in the residue was dissolved
in 400 µl of 0.05 M sodium acetate buffer pH 6.2. Aliquots of
100 µl were taken for the nucleotide determination using RIA
procedure with a cyclic AMP3H or cyclic GMP125I - RIA KITS
from Dupont New England Nuclear [25].
Drugs
Aminoguanidine, L-arginine, 8-bromo-cyclic GMP,
forskolin, L-NMMA, propranolol, atenolol, BAPTA and
trifluoperazine (TFP) (Sigma Chemical Company, Saint Louis,
Mo, USA); U-73122, ODQ and staurosporine (ICN
Pharmaceuticals Inc., Costa Messa, CA, USA); ZD 7114, SC
59230A, ICI 118,551, L-NIO and N-propyl-L-arginine (Tocris
Bioscience, Ellisville, Mo, USA). Stock solutions were freshly
prepared in the corresponding buffers.
Statistical Analysis
Student’s t-test for unpaired values was used to
determine the levels of significance. Analysis of variance
(ANOVA) and post hoc test (Dunnett´s Method and Student-
Newman-Keuls test) were employed when pair wise multiple
comparison procedure was necessary. Differences between
means were considered significant if P < 0.05.
Results
To analyze the expression of β adrenoceptor in skin
human fibroblasts, we studied the ability of [3H]-CGP to
bind to fibroblast membranes. Figure 1 shows the results
obtained from saturation binding assays (A) and Scatchard
analysis (B) indicated the presence of a single class of
high affinity specific binding site. The maximal number
of binding site (Bmax) was 222 ± 19 fmol/mg protein and
the equilibrium dissociation constant (Kd) was 20 ± 3
pM. The Ki values calculated from competitive binding
assays showed that fibroblasts express a high number of
β3 adrenoceptor subtypes (Table 1).
To define the physiological action of β3
adrenoceptors in these cells, the effects of a β3
adrenoceptor agonist on DNA synthesis and cAMP
production were studied. As shown in Figure 2, ZD 7114
induced a concentration-dependent decrease in both DNA
β3 Adrenergic Receptor on Fibroblast DNA Synthesis
hibition constants (Ki) for the competing agents were calculated
from the equation of Cheng and Prussoff: Ki = IC50/a ([3H]-
CGP) / Kd, where IC50 is the concentration of the competing
drug to inhibit 50% of the specific radioligand binding present
at a concentration of 0.5 nM. IC50 values were obtained from
competition experiments performed in duplicate at several
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synthesis (A) and cAMP production (B). These effects
were prevented by the specific β3 adrenoceptor antagonist
SR 59230A (1x10-7 M); indicating that the inhibition of
DNA synthesis and the decrement in basal cAMP are
direct effect triggered by the same receptor subtype. As
control, the direct activation of adenylate cyclase by
forskolin (1x10-4 M) was able to stimulate both DNA
synthesis (+48±2.3 %, n=5) and cAMP production
(+92.5±7%, n=6).
To determine if an endogenous nitric oxide (NO)
signaling system participates in the DNA synthesis
inhibition triggered by β3 adrenoceptor agonist, the effect
of different inhibitors of the enzymatic pathways involved
in NO and cGMP production were studied. Figure 3A
shows that ZD 7114 effect was prevented by the inhibition
of nitric oxide synthase (NOS) activity by L-NMMA
(1x10-5 M). The natural substrate of NOS, L-arginine
(5x10-5 M), reversed the L-NMMA effect. Figure 3B
shows that β3 adrenoceptor agonist increase in a
concentration-dependent manner NOS activity and this
effect was selectively blocked by SR 59230A.
Additionally, to examine the possibility that the
following steps of NO cascade activation would be
involved, the effect of a NO-sensitive guanylate cyclase
inhibitor (ODQ 5x10-5 M) was explored. Figure 4A shows
that ODQ 5x10-5 M impaired the inhibitory effect of ZD
7114 on DNA synthesis. The same Figure (4B) shows
the ability of the β3 adrenoceptor agonist to increase
production of cyclic GMP (cGMP) and the specific
inhibition by SR 59230A (1x10-7 M). As control, 1x10-4 M
8-bromo-cGMP (analogue to cGMP) was able to inhibit
fibroblast DNA synthesis (-45 ± 3.8%, n=5).
Figure 5 demonstrates a significant correlation
between decrease in DNA synthesis and decrease in
cAMP or increase in cGMP or stimulation of NOS
activity. This result indicates that β3 adrenoceptor agonist-
induced decrease in the DNA synthesis resulted in NOS/
guanylate cyclase stimulation and adenylate cyclase
inhibiton.
Fig. 1. 3H-CGP binding on human
skin fibroblast membranes. (A)
membranes (50 µg protein) were
incubated in the presence of
increasing 3H-CGP concentrations.
(B) equilibrium parameters calculated
from Scatchard plots were: Bmax 222
± 19 fmol/mg protein and Kd 20 ± 3
pM. Results are mean ± SEM of five
experiments performed in duplicate
Fig. 2. Decrease on 3H-Thymidine Incorporation (A) and in
cAMP (B) by increasing concentration of ZD 7114 ( ). The
inhibitory action of SR 59230A (1x10-7 M) is also shown ( ).
Values represent the mean ± SEM of six experiments in each
group performed by duplicate. Tissues were incubated for 30
min in presence or absence of SR 59230A and then ZD 7114
was added. Values of 3H-Thymidine Incorporation were
expressed as percentage of changes calculated by comparison
with the absolute values prior to the addition of ZD 7114. No
effects were observed with SR 59230A alone at the
concentration used either in DNA synthesis or in basal cAMP.
To determine whether enzymes involved in the NO/
cGMP signaling system could participate in the ZD 7114
inhibitory effect on DNA synthesis, the action of U-73122
and TFP were studied. Table 2 shows that the inhibition
of PLC by U-73122 (5x10-6 M) , calcium/calmodulin
(CaM) by TFP (5x10-6 M) prevented ZD 7114 effect.
Also, Table 2 shows that BAPTA (1x10-5 M) was able to
attenuate the inhibitory effect of ZD 7114 on DNA
synthesis. In order to assess whether the enzyme activities
are dependent on each other, fibroblasts were incubated
with different inhibitors of enzymatic pathways involved
in β3 adrenoceptor activation. Table 3 shows that U-73122,
TFP and L-NMMA inhibited the stimulatory action of
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Fig. 4. (A) Effect of 5x10-5 M ODQ ( ) on the dose-response
curve of ZD 7114 ( ) upon 3H-Thymidine Incorporation. (B)
The stimulation of cGMP accumulation by ZD 7114 alone ( )
or in the presence of SR 59230A ( ) is also shown. Values are
mean ± SEM of six experiments in each group performed by
duplicate. For other details see Figure 1.
Fig. 3. (A) Effect of 1x10-5 M L-NMMA ( ) on the action of
ZD 7114 ( ) upon DNA synthesis. Reversion of L-arginine
(5x10-5 M) ( ). No effects of L-arginine or L-NMMA alone
were obtained at the concentration used (data not shown). (B)
Stimulation in NOS activity by increasing concentration of ZD
7114 ( ) and the inhibition by treated fibroblasts with 1x10-7 M
SR 59230A ( ). Values are mean ± SEM of six experiments in
each group performed by duplicate. For other details see legends
of Figure 1.
ZD 7114 (1x10-7 M) upon NOS activity and cGMP
accumulation. The inhibition of PKC by staurosporine
(1x10-9 M) was without effect. Table 3 also shows that
1x10-4 M L-NIO (eNOS inhibitor) but not N-propyl-L-
arginine (nNOS inhibitor) or aminoguanidine (iNOS
inhibitor), prevented the stimulatory action of ZD 7114
on both NOS activity and cGMP accumulation.
Additionally, the inhibition of NO-sensitive guanylate
cyclase by ODQ (5x10-5 M) inhibited the ZD 7114 induced
increase in cGMP (-98±3%, n=5) but reverted the cAMP
inhibition (+19.7±2.2%, n=5). No effects were observed
with enzymatic inhibitors at the concentration used (data
not shown).
Discussion
The major new finding of this study is that ZD 7114,
a β3 agonist, exerted an inhibitory action on human skin
fibroblasts DNA synthesis. The ZD 7114 on DNA
synthesis was accompanied by a decrease on cAMP
production and with the increase amount of cGMP levels.
These effects were receptor-mediated action
demonstrated by the virtue of blockade by the selective
β3 adrenoceptor antagonist SR 59230A.
Our findings demonstrated that β3 adrenoceptor are
expressed in human fibroblast cells, displaying different
β  adrenoceptor populations, i.e. β3 > β2 > β1 as
demonstrated in binding assays with a β adrenoceptor
radiolabelled antagonist [3H]-CGP. Selective β
adrenoceptor antagonist subtypes (β3 : SD 59230A; β2 :
ICI 118,551; β1: atenolol) displaced with different
potencies [3H]-CGP binding; indicating by the competition
curves (Ki values) that fibroblast express a high number
of β3 and β2 adrenoceptors.
Functional evidences have shown that β1 and β2
adrenoceptors co-exist in fibroblasts and that their
stimulation produces increase in DNA synthesis and in
cAMP production [26, 27]. To our knowledge there have
been no previous reports as to a direct biological effect
of β3 adrenoceptor stimulation on human fibroblasts.
The mechanism of β3 adrenoceptor-induced inhibition
on skin fibroblast DNA synthesis was accompanied by a
decreased on cAMP production. In stark contrast with
the effect of ZD 7114, the stimulation of intracellular
cAMP production by forskolin, enhanced DNA synthesis;
indicating that cAMP generation (per se) provide a
sufficient stimulus for DNA synthesis of human skin
fibroblasts. The effect of cAMP on fibroblast DNA
synthesis is still unclear. Previous studies have
demonstrated a growth-inhibitory effect of cAMP [28,29]
although a stimulatory effect has also been reported [30].
β3 adrenoceptor differ from the β1 adrenoceptor and
β2 adrenoceptor subtypes by their molecular structure and
pharmacological profile. The β3 adrenoceptor gene
contains two introns [31, 32] leading to alternative splice
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Fig. 5. Correla-
tion in the effect of
ZD 7114 (1x10-12 to
1x10-7 M) on DNA
synthesis, on c-
AMP (R2 0.9994, P
value 0.0001),







plotted as a fun-
ction of cAMP or
cGMP production
or NOS activity.
Values are mean ±
SEM of six ex-
periments in each
group.
Table 2. Effect of different blockers in β3-agonist-induced
inhibition of DNA synthesis  Results are mean ± SEM of five
experiments in each group. * p < 0.001 comparing with ZD 7114
alone.
triggered by ZD 7114 on fibroblasts significantly correlated
with the decrement of cAMP and with the increment of
NO/cGMP production. These results suggest that β3
adrenoceptor stimulation-induced inhibition of DNA
synthesis as a resulted of adenylate cyclase inhibition and
NO/guanylate cyclase stimulation. The ability of cGMP
to induce inhibition of fibroblast DNA synthesis was
evidence by the results obtained with 8-bromo-cGMP that
mimicked ZD 7114 action and with ODQ that impaired
its. Our results also described that cGMP-elevating agents
like NO, suppress fibroblast DNA synthesis. The effect
of L-NMMA inhibiting the ZD 7114 agonist action on
fibroblast DNA synthesis, point to the role of NO-mediated
pathways on β3 adrenoceptor activation.
To investigate the nature of NOS involved, we
examined the influence of selective NOS inhibitors.
Detailed experimentation with selective inhibitors of
different NOS isozymes revealed that only L-NIO causes
a substantial inhibition of the ZD 7114 on NOS activity.
Inhibitors of iNOS and nNOS have no significant effect.
Recent studies [36] in the gastrointestinal tract are in
general agreement with the concept that eNOS is not
restricted to endothelial cells and that it also occurs in
other cells such as interstitial cells of Cajal [37], smooth
muscle cells [38] and cardiac myocytes [39].
In addition, our results propose that among
intracellular events triggers by ZD 7114 to inhibit DNA
synthesis, the activation of phosphoinositides turnover via
PLC occurs. In accord with this, experiments with U-
73122 prevented the inhibitory action of ZD 7114 on
fibroblast DNA synthesis. Moreover, the fact that CaM
inhibitor (TFP) and BAPTA abrogated the β3
adrenoceptor agonist action on DNA synthesis, point to
the release of calcium from cytoplasmatic stores being
responsible for the inhibitory action of ZD 7114. In
contrast, staurosporine, a PKC inhibitor, was unable to
alter ZD 7114 action on fibroblast. It was observed that
the increase of cytoplasmatic calcium resulted in inhibition
of cAMP production in brown adipocytes, through the
activation of calmodulin-controlled phosphodiesterase
activity. Under such conditions, fibroblast can produce
NO and NO alters the activities of adenylate cyclase
and phosphodiesterases, thus functional linking-the cAMP/
NO-cGMP pathways has been demonstrated [40, 41]. A
diagram to tie together the various systems studied and
proposing a model for the mechanisms where ZD 7114
down-regulates fibroblast DNA synthesis through NO/
cGMP pathway is shown in Figure 6.
In conclusion, this work demonstrates that β3
adrenoceptor stimulation decreases human skin fibroblast
isoforms, whereas β1 adrenoceptor and β2 adrenoceptor
genes are introless. β3 adrenoceptors are G-protein-
coupled receptors that interact with either Gs or Gi [33].
Depending on the tissue, β3 adrenoceptor stimulation
produces functional effects that are either comparable
with or opposite to those produced by β1 adrenoceptor
and β2 adrenoceptor stimulation. In adipose tissue, β3
adrenoceptor stimulation increases intracellular cAMP
production [34] but in the human heart, β3 adrenoceptor
mediate negative inotropic effects that is unlikely to be
related to stimulation of the cAMP production but rather
to stimulation of the cGMP pathway [33, 35].
In the present study, in which the expression levels
of β3 adrenoceptors is high, the inhibition of DNA synthesis
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Table 3. Effects of ZD 7114 upon NOS activity
and cGMP accumulation. Influence of enzymatic
inhibitors. Values are mean ± SEM of five
experiments in each group performed in duplicate.
NOS activity and cGMP accumulation were
measured after incubation for 30 min fibroblasts
with or without enzymatic inhibitors and with an
additional 1 min with 1x10-7 M ZD 71214. The
following concentrations were used: 5x10-6 M U-
73122 and TFP, 1x10-9 M staurosporine, 1x10-5 M
L-NMMA or 1x10-4 M L-NIO or N-propyl-L-
DNA synthesis through activation of cGMP/NOS
pathway with an inhibition of adenylate cyclase coupled
to β3 adrenoceptor activation. These data indicate that
constitutive β3 adrenoceptor coupling to Gi protein in
human skin fibroblast could serve both to restain Gs -
mediated activation by β2 and β1 adrenoceptor and to
initiate additional signal transduction pathways including
NO-cGMP. Changes in the expression of this pathway
may alter the balance between positive and negative effect
of catecholamines upon fibroblast DNA synthesis; so,
potentially altering the coordination required for wound
healing and tissue remodeling.
Acknowledgements
This work has been carried out by Grants from
CONICET, UBACYT and Argentine National Agency
for Investigation and Technology, Buenos Aires, Argentina
and the authors thank Mrs. Elvita Vannucchi and Mrs.
Fabiana Solari for their excellent technical assistance.
Fig. 6. Proposed model for the mechanism where ZD 7114 down-
regulates fibroblast DNA synthesis through NO/cGMP pathway.
ZD 7114 acting on G-protein-β3 adrenoceptors activates PLC,
mediating production of inositol-tri-phosphate (IP3) and 1-2
diacylglycerol (DAG). IP3 triggers intracellular release of calcium
(Ca++). Free Ca++ binds to calmodulin and the calcium/calmodulin
(CaM) activates eNOS with NO production. NO in turn stimulates
soluble guanylate cyclase with increase production of cyclic GMP
(cGMP). The increment of cGMP (+) and the decrement in cAMP (-
) triggers fibroblast DNA synthesis inhibition. The DAG-protein
kinase C (PKC) pathway appears not to participate in this
mechanism. Grey arrows indicate the site where the inhibitory
agents act.
arginine or aminoguanidine and 5x10-5 M ODQ. *p<0.001 comparing
with basal values (none); **p<0.001 comparing with ZD 7114 alone.
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